Epidermal Growth Factor Receptor C797S Mutant (EGFR C797S)

The Epidermal Growth Factor Receptor (EGFR) C797S mutant is a point mutation in the EGFR gene where cysteine 797 is replaced by serine. This mutation confers resistance to third-generation irreversible EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib and lazertinib by preventing these drugs from covalently binding to the receptor. It commonly arises after treatment with third-generation TKIs in patients with NSCLC whose tumors harbor sensitizing EGFR mutations and T790M. The allelic context of C797S (cis or trans with T790M) influences subsequent treatment options and efficacy.

Other names

EGFR cysteine 797 serine mutationEGFR C797S resistance mutationEGFR C797SERBB1 C797S

Prevents covalent binding of third-generation EGFR tyrosine kinase inhibitors (TKIs)